Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 633

1.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, Van der Kwast T, Wiegel T, Zattoni F, Heidenreich A.

Eur Urol. 2011 Apr;59(4):572-83. doi: 10.1016/j.eururo.2011.01.025. Epub 2011 Jan 25.

PMID:
21315502
2.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology.

Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12. Review.

PMID:
24321502
3.

[EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].

Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, van der Kwast T, Wiegel T, Zattoni F, Heidenreich A.

Actas Urol Esp. 2011 Nov-Dec;35(10):565-79. doi: 10.1016/j.acuro.2011.03.011. Epub 2011 Jul 14. Spanish.

PMID:
21757258
4.

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.

Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, van der Poel HG, van der Kwast TH, Rouvière O, Wiegel T, Mottet N.

Eur Urol. 2017 Apr;71(4):630-642. doi: 10.1016/j.eururo.2016.08.002. Epub 2016 Aug 31.

PMID:
27591931
5.

EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology.

Eur Urol. 2014 Jan;65(1):124-37. doi: 10.1016/j.eururo.2013.09.046. Epub 2013 Oct 6.

PMID:
24207135
6.

[EAU guidelines on prostate cancer. Part I: screening, diagnosis, and treatment of clinically localised disease].

Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel T, Zattoni F.

Actas Urol Esp. 2011 Oct;35(9):501-14. doi: 10.1016/j.acuro.2011.04.004. Epub 2011 Jul 14. Spanish.

PMID:
21757259
7.

EAU guidelines on prostate cancer.

Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, Zattoni F; European Association of Urology.

Eur Urol. 2008 Jan;53(1):68-80. Epub 2007 Sep 19. Review.

PMID:
17920184
8.

[EAU guidelines on prostate cancer].

Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, Zattoni F; European Association of Urology.

Actas Urol Esp. 2009 Feb;33(2):113-26. Review. Spanish.

PMID:
19418833
9.

Detectable prostate-specific antigen Nadir during androgen-deprivation therapy predicts adverse prostate cancer-specific outcomes: results from the SEARCH database.

Keto CJ, Aronson WJ, Terris MK, Presti JC, Kane CJ, Amling CL, Freedland SJ.

Eur Urol. 2014 Mar;65(3):620-7. doi: 10.1016/j.eururo.2012.11.052. Epub 2012 Dec 6.

10.

Treatment failure and clinical progression after salvage therapy in men with biochemical recurrence after radical prostatectomy: radiotherapy vs androgen deprivation.

Song C, Kim YS, Hong JH, Kim CS, Ahn H.

BJU Int. 2010 Jul;106(2):188-93. doi: 10.1111/j.1464-410X.2009.09136.x. Epub 2009 Dec 11.

11.

[Androgen deprivation for advanced prostate cancer].

Heidenreich A, Pfister D, Ohlmann CH, Engelmann UH.

Urologe A. 2008 Mar;47(3):270-83. doi: 10.1007/s00120-008-1636-2. Review. German.

PMID:
18273599
12.

Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.

Kijima T, Fujii Y, Yokoyama M, Ishioka J, Matsuoka Y, Numao N, Saito K, Koga F, Masuda H, Kawakami S, Kihara K.

BJU Int. 2012 Oct;110(8):1149-55. doi: 10.1111/j.1464-410X.2012.10959.x. Epub 2012 Feb 28.

13.

Phase I study of concurrent weekly docetaxel, high-dose intensity-modulated radiation therapy (IMRT) and androgen-deprivation therapy (ADT) for high-risk prostate cancer.

Chen RC, Rosenman JG, Hoffman LG, Chiu WK, Wang AZ, Pruthi RS, Wallen EM, Crane JM, Kim WY, Rathmell WK, Godley PA, Whang YE.

BJU Int. 2012 Dec;110(11 Pt B):E721-6. doi: 10.1111/j.1464-410X.2012.11536.x. Epub 2012 Sep 27.

14.

Endocrine treatment of prostate cancer.

Tammela T.

J Steroid Biochem Mol Biol. 2004 Nov;92(4):287-95. Epub 2004 Dec 31. Review.

PMID:
15663992
15.

Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer.

Nakabayashi M, Xie W, Buckle G, Bubley G, Ernstoff MS, Walsh W, Morganstern DE, Kantoff PW, Taplin ME.

Urology. 2013 Mar;81(3):611-6. doi: 10.1016/j.urology.2012.12.025.

PMID:
23452809
16.

EAU guidelines on prostate cancer.

Aus G, Abbou CC, Bolla M, Heidenreich A, Schmid HP, van Poppel H, Wolff J, Zattoni F; European Association of Urology.

Eur Urol. 2005 Oct;48(4):546-51. Review.

PMID:
16046052
17.

[LHRH analogues for the treatment of prostate cancer: an evidence level-based analysis].

Pfitzenmaier J, Altwein JE.

Aktuelle Urol. 2009 Mar;40(2):100-8. doi: 10.1055/s-0028-1098746. Epub 2009 Feb 27. Review. German.

PMID:
19253209
18.

[Change of the LHRH analogue in progressive castration-refractory prostate cancer].

Heidenreich A, Porres D, Epplen R, van Erps T, Pfister D.

Urologe A. 2012 Sep;51(9):1282-7. doi: 10.1007/s00120-012-2948-9. German.

PMID:
22733398
19.

Salvage radiotherapy for biochemical and clinical failures following radical prostatectomy.

Do T, Parker RG, Do C, Tran L, Do L, Dolkar D.

Cancer J Sci Am. 1998 Sep-Oct;4(5):324-30.

PMID:
9815297
20.

Evaluation and management of the man who has failed primary curative therapy for prostate cancer.

Ornstein DK, Oh J, Herschman JD, Andriole GL.

Urol Clin North Am. 1998 Nov;25(4):591-601. Review.

PMID:
10026768

Supplemental Content

Support Center